The estimated Net Worth of Gene Liau is at least 391 千$ dollars as of 28 December 2020. Gene Liau owns over 13,195 units of Stoke Therapeutics stock worth over 391,288$ and over the last 5 years he sold STOK stock worth over 0$. In addition, he makes 0$ as Executive Vice President、 Head of Research and Preclinical Development at Stoke Therapeutics.
Sign up
Gene Liau STOK stock SEC Form 4 insiders trading
Gene has made over 6 trades of the Stoke Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 13,195 units of STOK stock worth 7,917$ on 28 December 2020.
The largest trade he's ever made was exercising 37,851 units of Stoke Therapeutics stock on 16 October 2020 worth over 24,982$. On average, Gene trades about 13,385 units every 53 days since 2019. As of 28 December 2020 he still owns at least 26,546 units of Stoke Therapeutics stock.
You can see the complete history of Gene Liau stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gene Liau biography
Dr. Gene Liau Ph.D. serves as Executive Vice President, Head of Research and Preclinical Development of the Company. serves as Executive Vice President, Head of Research and Preclinical Development of the Company. From September 2015 to August 2017, Dr. Liau served as Senior Vice President and Head of Gene Therapy Research and Development at Precision Biosciences, Inc., a biotechnology company. From July 2011 to June 2015, Dr. Liau served in various roles at Pfizer, Inc., a pharmaceutical company, most recently as Executive Director and Head of External Research and Development Rare Diseases and Hematology. Dr. Liau holds a B.S. in Biology from the University of North Carolina at Chapel Hill and a Ph.D. in Biochemistry from Vanderbilt University.
How old is Gene Liau?
Gene Liau is 65, he's been the Executive Vice President、 Head of Research and Preclinical Development of Stoke Therapeutics since 2018. There are 4 older and 16 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.
What's Gene Liau's mailing address?
Gene's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.
Insiders trading at Stoke Therapeutics
Over the last 5 years, insiders at Stoke Therapeutics have traded over 49,612,288$ worth of Stoke Therapeutics stock and bought 4,288,550 units worth 94,976,062$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Investments, Lpwong Roderic...、Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of 1,639,987$. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth 6,000$.
What does Stoke Therapeutics do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
What does Stoke Therapeutics's logo look like?
Complete history of Gene Liau stock trades at Stoke Therapeutics
Stoke Therapeutics executives and stock owners
Stoke Therapeutics executives and other stock owners filed with the SEC include:
-
Stephen Tulipano,
Chief Financial Officer -
Dr. Edward M. Kaye,
CEO & Director -
Dr. Edward M. Kaye M.D., Ph.D.,
CEO & Director -
Huw Nash,
Chief Operating Officer, Chief Business Officer -
Barry Ticho,
Chief Medical Officer -
Edward Kaye,
Chief Executive Officer, Director -
Dr. Barry S. Ticho FACC, M.D., Ph.D.,
Chief Medical Officer -
Stephen J. Tulipano CPA, CPA, MBA,
Chief Financial Officer -
Seth Harrison,
Independent Chairman of the Board -
Jennifer Burstein,
Independent Director -
Adrian Krainer,
Independent Director -
Arthur Tzianabos,
Independent Director -
Arthur Levin,
Independent Director -
Dr. Adrian R. Krainer Ph.D.,
Co-Founder, Independent Director & Member of Scientific Advisory Board -
Garry Menzel,
Independent Director -
Julie Smith,
Independent Director -
Gene Liau,
Executive Vice President, Head of Research and Preclinical Development -
Dawn Kalmar,
Chief Communications Officer -
Jonathan Allan J.D.,
Deputy Gen. Counsel -
Dr. Gene Liau,
Chief Scientific Officer -
Dr. Huw M. Nash Ph.D.,
COO & Chief Bus. Officer -
Nancy M. Wyant,
VP & Head of Clinical Operations -
Shamim Ruff,
Chief Regulatory Officer -
Joan Wood,
Head of HR -
Isabel Aznarez Ph.D.,
Co-Founder, VP & Head of Biology -
Group, Llc Green Jeremy Red...,
-
Samuel W. Hall,
Director -
Life Science Ventures, L.P....,
-
Investments, Lpwong Roderic...,
-
Robin A. Walker,
Chief Legal Officer, CCO & Sec -
Jonathan Allan,
GENERAL COUNSEL & CORP SEC -
Trust Blue Horizon Enterpri...,
-
Thomas Leggett,
Chief Financial Officer -
Ian F Smith,